Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Major trial to find best drug for rare autoimmune disease

NCT ID NCT07010302

First seen Feb 18, 2026 · Last updated May 19, 2026 · Updated 17 times

Summary

This study compares five FDA-approved drugs to see which one works best to prevent relapses in people with NMOSD, a rare autoimmune disease that can cause blindness and paralysis. About 540 adults who test positive for a specific antibody will be randomly assigned to receive rituximab or one of four other medications. The goal is to find the safest and most effective treatment to help patients and doctors make better choices.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NMOSD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.